OMS103HP + Vehicle

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Knee Injuries

Conditions

Knee Injuries

Trial Timeline

Nov 1, 2004 → Mar 1, 2011

NCT ID

NCT00226759

About OMS103HP + Vehicle

OMS103HP + Vehicle is a phase 3 stage product being developed by Omeros Corporation for Knee Injuries. The current trial status is completed. This product is registered under clinical trial identifier NCT00226759. Target conditions include Knee Injuries.

What happened to similar drugs?

8 of 20 similar drugs in Knee Injuries were approved

Approved (8) Terminated (0) Active (12)

✅NISEDr. Reddy's LaboratoriesApproved

✅Capsaicin Topical SolutionAstellas PharmaApproved

🔄Duloxetine + PlaceboShionogiPhase 3

🔄DuloxetineShionogiPhase 3

🔄Duloxetine + PlaceboEli LillyPhase 3

🔄Duloxetine (DLX) + Placebo (PLA)Eli LillyPhase 3

🔄Duloxetine + placeboEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00624845	Phase 2/3	Completed	Dec 1, 2007	May 1, 2009	Postoperative Pain
NCT00226772	Phase 3	Completed	Jun 1, 2005	Mar 1, 2011	Knee Injuries
NCT00226759	Phase 3	Completed	Nov 1, 2004	Mar 1, 2011	Knee Injuries
NCT00245271	Phase 3	Completed	Oct 1, 2004	Mar 1, 2011	Anterior Cruciate Ligament Reconstruction

Competing Products

20 competing products in Knee Injuries

See all competitors

Product	Company	Stage	Hype Score
NISE	Dr. Reddy's Laboratories	Approved	40
NISELAT	Dr. Reddy's Laboratories	Pre-clinical	23
LY2828360 + Placebo	Eli Lilly	Phase 2	35
UBX0101 or placebo	Unity Biotechnology	Pre-clinical	8
UBX0101	Unity Biotechnology	Phase 1	19
UBX0101	Unity Biotechnology	Phase 2	25
UBX0101	Unity Biotechnology	Phase 1	19
YH23537 + Celecoxib + YH23537 placebo	Yuhan	Phase 2	35
YM150 + Warfarin	Astellas Pharma	Phase 2	35
ASP7962 + Naproxen + Placebo	Astellas Pharma	Phase 2	35
Capsaicin Topical Solution	Astellas Pharma	Approved	43
CGS-200-1 + CGS-200-5 + CGS-200 Vehicle	Astellas Pharma	Phase 2	35
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo	Sun Pharmaceutical	Phase 2	35
Duloxetine + Placebo	Shionogi	Phase 3	40
Duloxetine	Shionogi	Phase 3	40
V120083 + Naproxen + Placebo	Shionogi	Phase 2	35
ONO-4474 + Placebo matching ONO-4474	Ono Pharmaceutical	Phase 2	27
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine (DLX) + Placebo (PLA)	Eli Lilly	Phase 3	40
Duloxetine + placebo	Eli Lilly	Phase 3	40